Previous studies have shown that the acute administration of recombinant human erythropoietin (rhEPO) in a rat model of spinal cord injury (SCI) reduces lesion size, attenuates gliosis and microglia/macrophage activation as well as enhance myelinogenesis and improve locomotor outcome [29]. The gene discussed is EPO; the disease is spinal cord injury.